Harnessing albumin as a carrier for cancer therapies

[1]  Y. Liu,et al.  Floxuridine Homomeric Oligonucleotides "Hitchhike" with Albumin In Situ for Cancer Chemotherapy. , 2018, Angewandte Chemie.

[2]  Robert J. Lee,et al.  Folate receptor-targeted lipid-albumin nanoparticles (F-LAN) for therapeutic delivery of an Akt1 antisense oligonucleotide , 2018, Journal of drug targeting.

[3]  Emily B. Ehlerding,et al.  “Albumin Hitchhiking” with an Evans Blue Analog for Cancer Theranostics , 2018, Theranostics.

[4]  Ido D. Weiss,et al.  Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy , 2017, Nature Communications.

[5]  Yongzhuo Huang,et al.  Dual‐Targeting to Cancer Cells and M2 Macrophages via Biomimetic Delivery of Mannosylated Albumin Nanoparticles for Drug‐Resistant Cancer Therapy , 2017, Advanced Functional Materials.

[6]  A. Chakravarti,et al.  Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy. , 2017, Cancer research.

[7]  D. Schaffert,et al.  An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications , 2017, Molecular therapy. Nucleic acids.

[8]  F. Szymanowski,et al.  Endocytosis and intracellular traffic of cholesterol-PDMAEMA liposome complexes in human epithelial-like cells. , 2017, Colloids and surfaces. B, Biointerfaces.

[9]  Craig L Duvall,et al.  Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing , 2017, Proceedings of the National Academy of Sciences.

[10]  J. Kjems,et al.  Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  K. Ganjoo,et al.  Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas. , 2017 .

[12]  Hanadi F Sleiman,et al.  Development of DNA Nanostructures for High-Affinity Binding to Human Serum Albumin. , 2017, Journal of the American Chemical Society.

[13]  Ido D. Weiss,et al.  Novel “Add-On” Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents , 2017, The Journal of Nuclear Medicine.

[14]  Hongxu Lu,et al.  Influencing Selectivity to Cancer Cells with Mixed Nanoparticles Prepared from Albumin-Polymer Conjugates and Block Copolymers. , 2017, Bioconjugate chemistry.

[15]  I. V. Chernikov,et al.  Cholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene , 2017, Molecular therapy. Nucleic acids.

[16]  Yongzhuo Huang,et al.  Blood-Brain-Barrier-Penetrating Albumin Nanoparticles for Biomimetic Drug Delivery via Albumin-Binding Protein Pathways for Antiglioma Therapy. , 2016, ACS nano.

[17]  Xiaoyuan Chen,et al.  Albumin-Binding Evans Blue Derivatives for Diagnostic Imaging and Production of Long-Acting Therapeutics. , 2016, Bioconjugate chemistry.

[18]  Liangzhu Feng,et al.  Intelligent Albumin–MnO2 Nanoparticles as pH‐/H2O2‐Responsive Dissociable Nanocarriers to Modulate Tumor Hypoxia for Effective Combination Therapy , 2016, Advanced materials.

[19]  Freddie L. Pruitt,et al.  Abstract 2076: Albumin-linked proaerolysin based molecular grenades: A systemic therapeutic for disseminated castration resistant prostate cancer , 2016 .

[20]  Seung Woo Chung,et al.  Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor. , 2016, Biomaterials.

[21]  J. Wengel,et al.  An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[22]  Kristofer J. Thurecht,et al.  Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.

[23]  Hao Yang,et al.  Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Darrell J Irvine,et al.  Beyond antigens and adjuvants: formulating future vaccines. , 2016, The Journal of clinical investigation.

[25]  Nuno G. Azoia,et al.  Albumin-Based Nanodevices as Drug Carriers. , 2016, Current pharmaceutical design.

[26]  Hao Yang,et al.  Enhancing the circulating half-life and the antitumor effects of a tumor-selective cytotoxic peptide by exploiting endogenous serum albumin as a drug carrier. , 2016, International journal of pharmaceutics.

[27]  K. Howard,et al.  Albumin-based drug delivery: harnessing nature to cure disease , 2016, Molecular and Cellular Therapies.

[28]  Xiaoyuan Chen,et al.  Stable Evans Blue Derived Exendin-4 Peptide for Type 2 Diabetes Treatment. , 2016, Bioconjugate chemistry.

[29]  Xiaoyuan Chen,et al.  Chemical Conjugation of Evans Blue Derivative: A Strategy to Develop Long-Acting Therapeutics through Albumin Binding , 2016, Theranostics.

[30]  Jeffrey M. Sailstad,et al.  Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer , 2015, The Journal of allergy and clinical immunology.

[31]  Ashley M. Laughney,et al.  Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle , 2015, Science Translational Medicine.

[32]  Hong Liang,et al.  Developing Anticancer Copper(II) Pro-drugs Based on the Nature of Cancer Cells and the Human Serum Albumin Carrier IIA Subdomain. , 2015, Molecular pharmaceutics.

[33]  T. Kruse,et al.  Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. , 2015, Journal of medicinal chemistry.

[34]  S. Ghosh,et al.  Gold Nanocluster Embedded Albumin Nanoparticles for Two-Photon Imaging of Cancer Cells Accompanying Drug Delivery. , 2015, Small.

[35]  M. Hidalgo,et al.  SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial , 2015, Clinical Cancer Research.

[36]  Seung Won Shin,et al.  A novel albumin nanocomplex containing both small interfering RNA and gold nanorods for synergetic anticancer therapy. , 2015, Nanoscale.

[37]  M. V. Vander Heiden,et al.  Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. , 2015, Cancer research.

[38]  Inger Sandlie,et al.  Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics , 2015, Front. Immunol..

[39]  Seong Ho Choi,et al.  Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[40]  Ping Gong,et al.  Smart human serum albumin-indocyanine green nanoparticles generated by programmed assembly for dual-modal imaging-guided cancer synergistic phototherapy. , 2014, ACS nano.

[41]  Xin Wang,et al.  An albumin-based theranostic nano-agent for dual-modal imaging guided photothermal therapy to inhibit lymphatic metastasis of cancer post surgery. , 2014, Biomaterials.

[42]  Hong Liang,et al.  Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin. , 2014, European journal of medicinal chemistry.

[43]  Felix Kratz,et al.  A clinical update of using albumin as a drug vehicle - a commentary. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[44]  Fredrik Y Frejd,et al.  Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin‐binding domain allows for affinity purification and in vivo half‐life extension , 2014, Biotechnology journal.

[45]  D. Richardson,et al.  Unraveling the mysteries of serum albumin—more than just a serum protein , 2014, Front. Physiol..

[46]  X. Salvatella,et al.  Human serum albumin, systemic inflammation, and cirrhosis. , 2014, Journal of hepatology.

[47]  Zhongchan Sun,et al.  In Vivo Labeling of Serum Albumin for PET , 2014, The Journal of Nuclear Medicine.

[48]  S. Lippard,et al.  Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery , 2014, Journal of the American Chemical Society.

[49]  Dhiman Sarkar,et al.  Graphene quantum dots conjugated albumin nanoparticles for targeted drug delivery and imaging of pancreatic cancer. , 2014, Journal of materials chemistry. B.

[50]  Erkki Ruoslahti,et al.  A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[51]  Xiaoyang Xu,et al.  Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. , 2014, Advanced drug delivery reviews.

[52]  Gregory L. Szeto,et al.  Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.

[53]  So Jin Lee,et al.  Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors. , 2013, Biomaterials.

[54]  Leslie R Evans,et al.  Albumin as a versatile platform for drug half-life extension. , 2013, Biochimica et biophysica acta.

[55]  F. Thorsen,et al.  A Physiological Perspective on the Use of Imaging to Assess the In Vivo Delivery of Therapeutics , 2013, Annals of Biomedical Engineering.

[56]  Fredrik Y Frejd,et al.  Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule–Albumin-Binding Domain Fusion Protein , 2013, The Journal of Nuclear Medicine.

[57]  Christian M. Metallo,et al.  Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells , 2013, Nature.

[58]  W. Berger,et al.  Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery. , 2013, Chemical communications.

[59]  Subhas C. Kundu,et al.  Drug loading and release on tumor cells using silk fibroin–albumin nanoparticles as carriers , 2013, Nanotechnology.

[60]  R. Schibli,et al.  DOTA Conjugate with an Albumin-Binding Entity Enables the First Folic Acid–Targeted 177Lu-Radionuclide Tumor Therapy in Mice , 2013, The Journal of Nuclear Medicine.

[61]  M. Khorramizadeh,et al.  The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice. , 2012, International journal of pharmaceutics.

[62]  Jun Li,et al.  Bovine serum albumin nanoparticles modified with multilayers and aptamers for pH-responsive and targeted anti-cancer drug delivery , 2012 .

[63]  Ahmed O. Elzoghby,et al.  Albumin-based nanoparticles as potential controlled release drug delivery systems. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[64]  Felix Kratz,et al.  Impact of albumin on drug delivery--new applications on the horizon. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[65]  S. Prakash,et al.  Cationic Albumin Nanoparticles for Enhanced Drug Delivery to Treat Breast Cancer: Preparation and In Vitro Assessment , 2011, Journal of drug delivery.

[66]  I. V. Chernikov,et al.  Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group , 2011, Nucleic acids research.

[67]  R. Tan,et al.  Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy. , 2011, International journal of pharmaceutics.

[68]  P. Verroust,et al.  Cubilin is essential for albumin reabsorption in the renal proximal tubule. , 2010, Journal of the American Society of Nephrology : JASN.

[69]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[70]  Ru Jiang,et al.  Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles , 2010, International journal of nanomedicine.

[71]  Jianing Qi,et al.  Nanoparticles with dextran/chitosan shell and BSA/chitosan core--doxorubicin loading and delivery. , 2010, International journal of pharmaceutics.

[72]  Fredrik Y Frejd,et al.  Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications , 2010, FEBS letters.

[73]  I. Riemann,et al.  Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. , 2010, Biomaterials.

[74]  Alessandra Villa,et al.  New strategy for the extension of the serum half-life of antibody fragments. , 2009, Bioconjugate chemistry.

[75]  P. Soon-Shiong,et al.  SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. , 2009, Translational oncology.

[76]  T. Dobashi,et al.  Thermosensitive polymer-conjugated albumin nanospheres as thermal targeting anti-cancer drug carrier. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[77]  Sylvia Wagner,et al.  Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. , 2008, Bioconjugate chemistry.

[78]  L. Abrahmsén,et al.  Engineering of a femtomolar affinity binding protein to human serum albumin. , 2008, Protein engineering, design & selection : PEDS.

[79]  C. R. Leemans,et al.  Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology , 2008, Molecular Cancer Therapeutics.

[80]  Christof Baltes,et al.  A portable albumin binder from a DNA-encoded chemical library. , 2008, Angewandte Chemie.

[81]  U. Müller-Ladner,et al.  Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis , 2008, Annals of the rheumatic diseases.

[82]  L. Bolondi,et al.  Efficacy of doxorubicin coupled to lactosaminated albumin on rat hepatocellular carcinomas evaluated by ultrasound imaging. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[83]  J. Bading,et al.  Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. , 2008, Nuclear medicine and biology.

[84]  L. B. Knudsen,et al.  Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness. , 2007, Journal of medicinal chemistry.

[85]  R. Kontermann,et al.  A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. , 2007, Protein engineering, design & selection : PEDS.

[86]  Frank J Rybicki,et al.  Biochemical safety profiles of gadolinium‐based extracellular contrast agents and nephrogenic systemic fibrosis , 2007, Journal of magnetic resonance imaging : JMRI.

[87]  J. Drevs,et al.  Phase I and Pharmacokinetic Study of the (6-Maleimidocaproyl)Hydrazone Derivative of Doxorubicin , 2007, Clinical Cancer Research.

[88]  Dongmei Cun,et al.  Preparation, characterization and biodistribution of the lactone form of 10-hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. , 2007, International journal of pharmaceutics.

[89]  I. Fichtner,et al.  Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. , 2007, Bioconjugate chemistry.

[90]  Guangzhao Zhang,et al.  Nanogels prepared by self-assembly of oppositely charged globular proteins. , 2006, Biopolymers.

[91]  K. Strebhardt,et al.  Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. , 2006, Biomaterials.

[92]  M. Michaelis,et al.  Covalent Linkage of Apolipoprotein E to Albumin Nanoparticles Strongly Enhances Drug Transport into the Brain , 2006, Journal of Pharmacology and Experimental Therapeutics.

[93]  M. Tattersall,et al.  Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review , 2006, Supportive Care in Cancer.

[94]  F. Jankevicius,et al.  Phase II study of MTX-HSA in combination with Cisplatin as first line treatment in patients with advanced or metastatic transitional cell carcinoma , 2006, Investigational New Drugs.

[95]  J. Benítez,et al.  Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer , 2006, Breast Cancer Research and Treatment.

[96]  Patrick Soon-Shiong,et al.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[97]  E. Christensen,et al.  Renal albumin absorption in physiology and pathology. , 2006, Kidney international.

[98]  A. Rawat,et al.  Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles , 2006, Journal of drug targeting (Print).

[99]  P. Wei,et al.  Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice , 2005, Cancer Immunology, Immunotherapy.

[100]  M. Lisanti,et al.  Caveolin-1 in oncogenic transformation, cancer, and metastasis. , 2005, American journal of physiology. Cell physiology.

[101]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[102]  I. Fichtner,et al.  Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug carboplatin designed as albumin-binding prodrugs. , 2004, Bioconjugate chemistry.

[103]  K. Strebhardt,et al.  Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[104]  P. M. Campbell,et al.  Oncogenic Ras and its role in tumor cell invasion and metastasis. , 2004, Seminars in cancer biology.

[105]  I. Fichtner,et al.  A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. , 2003, Cancer research.

[106]  F. Kratz,et al.  Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy. , 2003, Bioconjugate chemistry.

[107]  D. Rognan,et al.  Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. , 2002, Journal of medicinal chemistry.

[108]  T. Oshikiri,et al.  Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma , 2002, British Journal of Cancer.

[109]  S. Woodman,et al.  Caveolae: From Cell Biology to Animal Physiology , 2002, Pharmacological Reviews.

[110]  M. Otagiri,et al.  Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. , 2002, Biological & pharmaceutical bulletin.

[111]  B. V. van Rhijn,et al.  A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy , 2002, Cancer Chemotherapy and Pharmacology.

[112]  P. Oh,et al.  Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: A pathway to overcome cell barriers to drug and gene delivery , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[113]  David S. Park,et al.  Caveolae-deficient Endothelial Cells Show Defects in the Uptake and Transport of Albumin in Vivo * , 2001, The Journal of Biological Chemistry.

[114]  V. Bhakta,et al.  A Barbourin-albumin Fusion Protein that Is Slowly Cleared In Vivo Retains the Ability to Inhibit Platelet Aggregation In Vitro , 2001, Thrombosis and Haemostasis.

[115]  M. Gumbleton.  Caveolae as potential macromolecule trafficking compartments within alveolar epithelium. , 2001, Advanced drug delivery reviews.

[116]  H. Fiebig,et al.  Pre‐clinical evaluation of a methotrexate–albumin conjugate (MTX‐HSA) in human tumor xenografts in vivo , 2001, International journal of cancer.

[117]  M. Ittmann,et al.  Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. , 2001, Cancer research.

[118]  H Birn,et al.  Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. , 2000, The Journal of clinical investigation.

[119]  T. Nguyen,et al.  The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A protein. , 1999, Vaccine.

[120]  P. Brick,et al.  Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites , 1998, Nature Structural Biology.

[121]  R. Dolan,et al.  MS-325: albumin-targeted contrast agent for MR angiography. , 1998, Radiology.

[122]  C. Unger,et al.  Albumin Conjugates of the Anticancer Drug Chlorambucil: Synthesis, Characterization, and In Vitro Efficacy , 1998, Archiv der Pharmazie.

[123]  A. Wunder,et al.  Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia. , 1997, Critical reviews in oncology/hematology.

[124]  P. Oh,et al.  Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. , 1994, The Journal of biological chemistry.

[125]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[126]  B Hammarberg,et al.  Dual affinity fusion approach and its use to express recombinant human insulin-like growth factor II. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[127]  E. Nielsen,et al.  Isolation and characterization of a 14-kDa albumin-binding fragment of streptococcal protein G. , 1988, Journal of immunology.

[128]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[129]  U Kragh-Hansen,et al.  Molecular aspects of ligand binding to serum albumin. , 1981, Pharmacological reviews.

[130]  P. White,et al.  Enhanced extravasation, stability and in vivo cardiac gene silencing via in situ siRNA-albumin conjugation. , 2012, Molecular pharmaceutics.

[131]  B. Rothen‐Rutishauser,et al.  Differences in the Intracellular Distribution of Acid-Sensitive Doxorubicin-Protein Conjugates in Comparison to Free and Liposomal Formulated Doxorubicin as Shown by Confocal Microscopy , 2004, Pharmaceutical Research.

[132]  O. Pickeral,et al.  An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. , 2003, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[133]  T. W. Evans.  Albumin as a drug: biological effects of albumin unrelated to oncotic pressure , 2002 .

[134]  D C Carter,et al.  Structure of serum albumin. , 1994, Advances in protein chemistry.